(Q37600385)

21 August 2017

1 reference

title

Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria (English)

1 reference

21 August 2017

main subject

gram-positive bacteria

0 references

author name string

George M Eliopoulos

series ordinal

1

1 reference

21 August 2017

publication date

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

59 Suppl 1

1 reference

21 August 2017

page(s)

S17-24

1 reference

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activities of tigecycline against clinical isolates from Shanghai, China

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Surveillance of linezolid resistance in Germany, 2001-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

United States resistance surveillance results for linezolid (LEADER Program for 2007).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antipneumococcal activity of dalbavancin compared to other agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Recombination Proficiency Influences Frequency and Locus of Mutational Resistance to Linezolid in Enterococcus faecalis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Antimicrobial resistance to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid resistance in clinical isolates of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid: The First Oxazolidinone Antimicrobial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Resistance studies with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In-vitro activity of LY 146032, a novel cyclic lipopeptide, alone and in combination with gentamicin or tobramycin against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960004-9

7 January 2021

10.1016/S0163-4453(09)60004-9

Identifiers

DOI

1 reference

21 August 2017

1 reference